Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Chuikyo Reps Back Greater Transparency, but Lean toward Broader CEA Price Cuts
Provider and payer members of a key reimbursement policy panel signaled support on September 9 for the broader use of Japan’s cost-effectiveness assessment (CEA) system to cut drug prices, even as both sides acknowledged the need to improve transparency in…
To read the full story
Related Article
- CEA Transparency Gains Welcome, but Guidelines Need Scrutiny: Economist
September 30, 2026
- More Company Involvement in CEA a Big Positive: C2H Researcher
September 29, 2026
- Pharma Groups Press for Freeze on CEA Price Cuts, Cite Unresolved Issues
September 17, 2026
- CEA Review Finds Past Decisions Sound, Sees Room for More Transparency
September 8, 2026
- CEA Review Group Wraps Up Technical Debate, Urges More Company Access
August 19, 2026
- CEA Review Group Debates Draft Report, Eyes August 18 Wrap-Up
August 5, 2026
- CEA Review Group Debates Comparator Technologies, ICER Uncertainty
July 14, 2026
- CEA Review Group Discusses Evidence for Additional Usefulness
June 17, 2026
- CEA Review Group Holds First Meeting, Technical Debate Yet to Begin
May 26, 2026
- Are Technical Discussions Enough for Japan’s CEA System?
May 25, 2026
- JPMA Exec Urges Broader Debate on Japan’s CEA System
May 22, 2026
- Japan to Start CEA Technical Discussions as Early as May 25
May 20, 2026
- Japan to Launch CEA “Technical Discussions” under MHLW Research Group
May 14, 2026
- Uncertainty Clouds Start of 6-Month CEA “Technical Discussions”
April 7, 2026
- Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead
January 19, 2026
- Expert Calls for Full Verification of CEA Guidelines and Analytical Frameworks
January 16, 2026
- Japan Puts CEA Expansion on Hold, Sets 6-Month “Technical Discussions”
December 26, 2025
- Industry Opposes Deeper CEA Price Cuts for “Cost-Increase” Products
November 13, 2025
- Japan to Clarify Criteria for Upward Price Adjustments under CEA Scheme
October 16, 2025
- Deeper CEA Price Cuts Mooted for “Cost Increase” Products: FY2026 Reform Debate
October 16, 2025
- Rift Surfaces over What Constitutes “Objective Review” of CEA
September 29, 2025
- Industry Urges “Objective Review First” for CEA Reform; Payers Push for Expansion
August 7, 2025
REGULATORY
- Label Revisions Ordered for Checkpoint Inhibitors over Gastritis, Esophagitis
September 30, 2026
- MHLW Panel Backs Easing Protopic Contraindication for Young Children
September 30, 2026
- PMDA Flags New Safety Risks with 3 Drugs
September 30, 2026
- CEA Transparency Gains Welcome, but Guidelines Need Scrutiny: Economist
September 30, 2026
- More Company Involvement in CEA a Big Positive: C2H Researcher
September 29, 2026
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
The development of Boehringer Ingelheim’s survodutide is gathering pace, putting the GLP-1/glucagon receptor agonist in contention to become the next…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…